BMY Targets Real-World Edge for Ozanimod in Ulcerative Colitis

Bristol-Myers Squibb Company (BMY) announced an update on their ongoing clinical study.

Bristol-Myers Squibb (BMY) is running a real-world chart review study called “Real-world Effectiveness of Ozanimod in Patients With Steroid-Dependent Ulcerative Colitis: A Chart Review Study.” It aims to compare how well ozanimod works versus older steroid-sparing drugs in everyday practice in Japan and how safe it is for people with ulcerative colitis.

The study compares two oral drugs used to keep ulcerative colitis under control. One group receives ozanimod, BMY’s newer therapy, while the other receives azathioprine, a long-used immune-suppressing medicine often used to reduce or replace steroids in these patients.

This is an observational, retrospective cohort study, meaning doctors look back at existing patient charts rather than assigning treatments. There is no random assignment or masking, so the goal is not to test cause and effect but to see how these drugs perform in real clinics under routine care.

The trial was first submitted on November 27, 2025, signaling when the formal plan entered the public record. The latest update was filed on March 12, 2026, showing that the protocol and status have been recently refreshed and that the project is still active and refining its data plan.

For investors, this update matters because strong real-world results could support broader use of ozanimod and help defend BMY’s share in inflammatory bowel disease. Positive findings versus azathioprine may reinforce pricing power and label positioning versus rivals in the ulcerative colitis space and could lift sentiment on BMY’s long-term growth story.

The study remains ongoing and updated, with further details available on the ClinicalTrials portal.

To learn more about BMY’s potential, visit the Bristol-Myers Squibb Company drug pipeline page.